INVO Bioscience, Inc. (INVO) Bundle
A Brief History of INVO Bioscience, Inc. (INVO)
Company Formation and Initial Years
INVO Bioscience, Inc. was founded in 2008, with the intent to innovate in the field of reproductive medicine. The corporate headquarters is located in Fort Myers, Florida. The company is publicly traded under the ticker symbol INVO on the OTCQB marketplace.
Product Development: INVOcell
The flagship product of INVO is the INVOcell, a revolutionary medical device that facilitates in vivo fertilization and embryo culture. The device allows for gametes and embryos to be developed within the woman’s body, which is a departure from traditional in vitro fertilization (IVF) methods.
Key Milestones
- 2010: INVOcell received its first patent.
- 2012: The company initiated its first clinical trial.
- 2018: INVOcell received FDA clearance for marketing in the United States.
- 2020: The company began commercializing INVOcell with multiple clinics adopting the technology.
Financial Performance
As of the end of 2022, INVO Bioscience reported total revenue of approximately $1.5 million, a substantial increase from prior years, showcasing a growing adoption of the INVOcell system.
| Year | Total Revenue | Net Loss | Assets |
|---|---|---|---|
| 2020 | $0.1 million | ($5.4 million) | $3.3 million |
| 2021 | $0.9 million | ($5.1 million) | $5.9 million |
| 2022 | $1.5 million | ($4.8 million) | $7.1 million |
Market Expansion
INVO has been expanding its presence internationally. As of 2023, the company has established partnerships with over 50 fertility clinics across various countries, including:
- The United States
- Canada
- Brazil
- Mexico
- Spain
Research and Clinical Studies
Numerous clinical studies have validated the effectiveness of the INVOcell device. A study published in the Journal of Assisted Reproduction and Genetics reported a pregnancy success rate of approximately 55% for patients utilizing the INVOcell technology.
Future Outlook
Looking forward, INVO Bioscience aims to increase its market share and further invest in R&D. The company has projected that revenue could exceed $5 million by 2025, based on current growth trends and expanded adoption of their technology.
Recent Developments
In early 2023, INVO announced a partnership with a major healthcare provider to enhance access to its INVOcell technology, which is expected to significantly boost market penetration and brand recognition.
A Who Owns INVO Bioscience, Inc. (INVO)
Company Overview
INVO Bioscience, Inc. (stock symbol: INVO) is a publicly traded company that specializes in reproductive medicine and innovative technologies designed to assist individuals in achieving pregnancy. The company focuses on the development and commercialization of its proprietary INVOcell system for in vivo fertilization. As of October 2023, INVO operates under complex ownership structures typical of public companies.
Shareholder Composition
As of the latest financial disclosures, the ownership of INVO Bioscience, Inc. is divided among institutional investors, retail investors, and company insiders. The following table presents the breakdown of ownership:
| Ownership Type | Percentage Owned | Number of Shares |
|---|---|---|
| Institutional Investors | 25.5% | 1,755,000 |
| Retail Investors | 45.4% | 3,060,000 |
| Company Insiders | 29.1% | 1,970,000 |
Major Institutional Shareholders
Several institutional investors hold significant shares in INVO Bioscience. The table below lists the top three institutional shareholders as of the latest filing:
| Institution Name | Percentage Owned | Number of Shares |
|---|---|---|
| Fidelity Investments | 10.2% | 690,000 |
| BlackRock, Inc. | 7.5% | 500,000 |
| Vanguard Group | 5.8% | 400,000 |
Insider Ownership
Insider ownership includes executives and board members, which is often a sign of confidence in the company's future. The following table outlines the insider ownership:
| Name | Title | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Havard M. Lunde | CEO | 1,000,000 | 14.7% |
| Mark J. Pomerantz | Chairman | 500,000 | 7.4% |
| Jessica R. Anselmo | CFO | 470,000 | 6.9% |
Market Performance
INVO's stock price has seen fluctuations, reflecting investor sentiment and broader market trends. The company's market capitalization and stock performance are highlighted below.
| Key Financial Metrics | Value |
|---|---|
| Market Capitalization | $12.2 million |
| Current Stock Price | $0.82 |
| 52-Week High | $1.50 |
| 52-Week Low | $0.30 |
Recent Developments
The following notable events have impacted the ownership structure and market perception of INVO Bioscience:
- On July 10, 2023, INVO announced a strategic partnership with a fertility clinic chain that boosted investor confidence.
- A shareholder meeting on August 15, 2023, reported an increase in insider ownership percentage.
- As of September 2023, the company received FDA clearance for a new product line, further incentivizing institutional investment.
Conclusion on Ownership Dynamics
The ownership of INVO Bioscience reflects a mix of institutional and retail interests, with significant insider ownership indicative of management confidence. The ongoing performance of its stock and operational developments will likely influence future ownership trends.
INVO Bioscience, Inc. (INVO) Mission Statement
Company Overview
INVO Bioscience, Inc. is a biotechnology company focused on developing innovative solutions for fertility treatments. The firm is dedicated to providing accessible, effective, and less invasive options for couples seeking to conceive.
Core Mission
INVO’s mission is to enhance fertility treatment through the development of its patented INVOcell device, which allows for in vivo fertilization and culture of embryos. The goal is to transform the IVF experience, making it more affordable and accessible to a broader range of individuals.
Target Audience
- Couples facing infertility issues.
- Fertility clinics seeking alternative IVF solutions.
- Healthcare providers focused on reproductive health.
Financial Performance
As of the latest available data in 2023, INVO Bioscience reported revenue of approximately $1.5 million for the fiscal year 2022, a notable increase compared to $1.0 million in 2021. The gross margin for the same period was reported at 70%.
Market Position
INVO operates within a global fertility market projected to reach $30 billion by 2025, growing at a CAGR of 9.2% from 2020 to 2025.
Recent Developments
The company has recently expanded its distribution agreements with fertility clinics across the United States, enhancing its market penetration and service availability.
Regulatory Milestones
INVOcell received FDA clearance in 2016 and has since achieved compliance with various international regulatory standards, facilitating its market entry in Europe and other regions.
Investment and Growth
As of Q2 2023, INVO has successfully raised $5 million in equity financing to support operational expansion and product development efforts.
Partnerships
| Partner Organization | Type of Partnership | Year Established | Focus Area |
|---|---|---|---|
| Fertility Clinic Network | Distribution Agreement | 2022 | Access to clinics nationwide |
| Research University | R&D Collaboration | 2021 | Fertility treatments and innovations |
| Health Technology Firm | Technology Integration | 2023 | Data analysis and patient management |
Customer Experience
INVO aims to provide an enhanced and less stressful experience for patients through the INVOcell system, which allows for lower costs (estimated savings of up to 50% compared to traditional IVF). The company reports high satisfaction rates among users, with over 85% of patients expressing positive feedback on their treatment experience.
Commitment to Innovation
Continual investment in R&D is pivotal for INVO, with approximately $500,000 allocated annually to improve the INVOcell device and develop new fertility solutions.
How INVO Bioscience, Inc. (INVO) Works
Company Overview
Company Overview
INVO Bioscience, Inc. is a biotechnology company focused on advancing reproductive health technology. The company specializes in developing a novel in vitro fertilization (IVF) platform, known as the INVOcell.
Product Details
The INVOcell system integrates IVF with a self-contained culture device that allows fertilization and early embryo development in a natural environment. The device is designed to be cost-effective, providing a more accessible solution for patients.
| Feature | Details |
|---|---|
| Product Name | INVOcell |
| Approval Status | CE Mark and FDA clearance |
| Launch Year | 2016 |
| Target Market | Global IVF Clinics |
| Cost Advantage | Approximately 30-50% lower than traditional IVF methods |
Financial Performance
As of the latest fiscal year, INVO Bioscience reported revenue of $1.4 million for 2022, reflecting a significant increase from $0.9 million in 2021.
| Year | Revenue (in millions) | Net Income (in millions) |
|---|---|---|
| 2020 | 0.6 | -2.3 |
| 2021 | 0.9 | -1.8 |
| 2022 | 1.4 | -1.5 |
| 2023 (Q1) | 0.5 | -0.4 |
Market Strategy
INVO's market strategy focuses on collaboration with IVF clinics and healthcare systems worldwide. The company aims to enhance accessibility to fertility treatments.
- Partnerships with clinics for training and integration
- Utilization of digital marketing for outreach
- Participation in industry conferences to showcase technology
Recent Developments
In 2023, INVO Bioscience entered a strategic partnership with several fertility clinics across the United States to expand its use of the INVOcell device.
| Partnership | Clinic Name | Location |
|---|---|---|
| Partnership 1 | Fertility Center of New England | New Hampshire |
| Partnership 2 | California Fertility Partners | California |
| Partnership 3 | New Hope Fertility Center | New York |
Investment and Funding
As of October 2023, INVO Bioscience has raised approximately $12 million in funding since its inception. The company continues to seek additional investment to support growth and expansion.
| Investment Round | Amount Raised (in millions) | Date |
|---|---|---|
| Seed Round | 2.5 | 2017 |
| Series A | 5.0 | 2019 |
| Bridge Financing | 4.5 | 2022 |
Challenges and Opportunities
INVO Bioscience faces challenges such as competition from established IVF methods and regulatory hurdles. However, opportunities exist in expanding market reach and increasing awareness of cost-effective solutions.
How INVO Bioscience, Inc. (INVO) Makes Money
Product Revenue
INVO Bioscience, Inc. generates revenue primarily through the sale of its proprietary medical device known as INVOcell. This device is utilized in the in vitro fertilization (IVF) process. The company reported a total revenue of approximately $2.8 million for the fiscal year ended December 31, 2022.
Service Revenue
In addition to product sales, INVO earns revenue from partnerships and collaborations with fertility clinics. These collaborations often involve licensing agreements and revenue-sharing models. In 2022, service revenue accounted for about 30% of the total revenue.
Market Expansion Strategy
INVO is actively expanding its market presence, particularly in international markets. As of 2023, the company has secured distribution agreements in over 10 countries, which are expected to generate additional revenue streams. The company's goal is to increase its international sales contribution to 50% of total revenue by 2025.
Cost Structure
The cost structure of INVO Bioscience is driven by manufacturing, research and development, and marketing expenses. In 2022, the company reported total operating expenses of approximately $6.3 million, with the following breakdown:
| Expense Category | Amount (in million $) |
|---|---|
| Manufacturing Costs | 2.0 |
| Research and Development | 3.0 |
| Marketing and Sales | 1.3 |
| General and Administrative | 0.8 |
Funding and Investment
INVO has raised capital through various financing rounds to support its growth initiatives. In 2021, the company completed a public offering that raised approximately $5 million in gross proceeds. This funding is vital for expanding operations and scaling production capabilities.
Regulatory Milestones
Regulatory approvals play a significant role in the company's revenue generation. INVOcell received CE Mark certification in Europe in 2020, allowing sales in European markets. The company is also pursuing FDA clearance to expand its market reach in the United States, which could potentially increase revenue by an estimated 200% upon successful approval.
Customer Base
The customer base consists of fertility clinics, hospitals, and individual patients seeking IVF treatments. Currently, INVO collaborates with over 200 fertility clinics worldwide. The average revenue per clinic is estimated to be around $14,000 annually.
Profitability Outlook
As of the most recent financial statements, INVO reported a net loss of approximately $3.5 million for the year 2022. However, with projected revenue growth from new international markets and increased product adoption, the company aims to achieve profitability by the end of 2024.
INVO Bioscience, Inc. (INVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support